Previous evidence has suggested that statins could have an effect on non-CVD outcomes. To examine the quality, validity, and credibility of evidence of this association, the researchers conducted a...
In a recent study, researchers sought to examine treatment patterns, healthcare utilization, and costs among patients diagnosed with schizophrenia receiving oral therapy vs long-acting injectable...
Variability in metabolic parameters has been shown to have an effect on health outcomes, but whether they have an additive effect on mortality risk and cardiovascular outcomes in the general population is...
While patients with schizophrenia are known to have an increased risk of obesity and metabolic disease, knowledge regarding eating behaviors in this patient population is still limited.
Using National Health Insurance claims data from patients with schizophrenia and type 2 diabetes in Taiwan, researchers sought to investigate the prevalence and characteristics of schizophrenia in this...
Following a systematic evidence review, the US Preventive Services Task Force has released updates to its 2012 recommendations on screening for obesity in adults.
Following a review of over 400 studies, the American Heart Association has updated its 2008 guidelines on the detection and management of resistant hypertension.
In a secondary analysis of the ENCORE trial, researchers sought to examine the effects of the DASH diet alone and in combination with exercise on the need for antihypertensive medication in overweight and...
In a recent report, the CDC sought to establish a baseline for the CVD risk factors targeted for reduction by the Million Hearts 2022 initiative during 2017–2021 and highlights recent changes over time.
...
